Table 7.
Outcomes predicted by models for one birth cohort in Afr-region
| POLYMODa | Roxanne | CoRoVa | |
|---|---|---|---|
| Undiscounted cases | |||
| Mild | 92,989 | 121,312 | 128,807 |
| Moderate | 49,051 | 70,126 | 54,559 |
| Severe | 5,092 | 9,589 | 5,277 |
| Nosocomial | 1,680 | 1,986 | 2,701 |
| Deaths | 955 | 1,789 | 1,524 |
| Outpatient | 54,143 | 70,126 | 54,559 |
| Inpatient (comm. acq.) | 5,092 | 9,589 | 5,277 |
| Discounted savings | |||
| Outpatient | $568,502 | $716,305 | $623,977 |
| Inpatient | $973,247 | $1,329,538 | $753,884 |
| Indirect | $108,916 | $106,377 | $81,486 |
| Discounted net costsb (*1000) | $6,759 | $ 8,757-17,094 | $ 9,250-17,467 |
| Discounted QALYs | |||
| Mortality | 24,962 | 45,817 | 39,070 |
| Morbidity | 542 | 762 | 628 |
a. Approximation for one cohort from the multi-cohort results; b. Health-care perspective and range given for previous upper and lower vaccine prices if appropriate.